kaftrio的用法用量

Kaftrio is an innovative triple therapy drug, consisting of ivacaftor, tezacaftor and elexacaftor, specifically used to treat cystic fibrosis (CF). The drug significantly improves patients' lung function and quality of life by targeting and repairing CFTR protein functional defects. Kaftrio is suitable for CF patients aged 2 years and above. Patients of different age groups and liver function status require differentiated dosing regimens.

Kaftrio usage and dosage

The dosage regimen needs to be individually adjusted according to the patient's age and liver function status to ensure the best therapeutic effect.

Recommended dosage for adult and pediatric patients

Children 2 to 6 years old: 1 packet of oral granules in the morning and evening; children 6 to 12 years old: 2 tablets of the combination preparation in the morning and 1 ivacaftor tablet in the evening; patients 12 years and above: 2 tablets of the combination preparation in the morning and 1 ivacaftor tablet in the evening. All doses should be taken with fatty foods to enhance absorption.

Dose adjustment in patients with hepatic impairment

Patients with mild hepatic impairment (Child-Pugh class A) do not need to adjust the dose, but liver function needs to be closely monitored. In patients with moderate hepatic impairment (Child-Pugh class B), use should be considered only when the benefits outweigh the risks, and a reduced dose is required. It is contraindicated in patients with severe hepatic impairment.

Precautions for Medication

Tablets should be swallowed whole, and granules should be mixed with soft food. If you miss a dose, you should take it as soon as possible, but if it is less than 6 hours before the next dose, skip it. Avoid coadministration with strong CYP3A inhibitors and adjust the dose if necessary.

Patients should strictly follow the individualized dosage regimen.

Side effects of Kaftrio

Kaftrio treatment may cause a variety of adverse reactions, and timely recognition and treatment are crucial to the continuity of treatment.

Common adverse reactions

Including headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, nasal congestion, rhinorrhea, rhinitis, influenza, sinusitis, etc. These symptoms are mostly mild to moderate and usually do not affect continued treatment.

Laboratory test abnormalities

Alanine aminotransferase (ALT), creatine phosphokinase (CPK), aspartate aminotransferase (AST) and blood bilirubin may be elevated. Liver function indicators need to be monitored regularly and the treatment plan adjusted if necessary.

Management of adverse reactions

Mild adverse reactions can be treated symptomatically, while severe liver function abnormalities require dose reduction or suspension of medication. Persistent headache or severe rash should seek medical evaluation. Symptoms of respiratory infection require prompt treatment.

Understanding the side effect characteristics of Kaftrio can help early intervention and improve treatment safety.

Usage of Kaftrio in special populations

Special populations need to pay special attention to dose adjustment and monitoring requirements when using Kaftrio.

Pediatric patients

The safety of the drug in children under 2 years of age has not been established. Children aged 2 to 6 years old use granules, and children aged 6 to 12 years old use a combination of compound preparation and ivacaftor. Growth and development indicators need to be evaluated regularly.

Pregnant and lactating women

Pregnant women need to carefully evaluate the risk-benefit ratio when using it. Breastfeeding women should suspend breastfeeding as the drug ingredients may be excreted through breast milk.

Elderly patients

Elderly patients usually do not need to adjust the dose, but due to the possibility of comorbidity with other diseases and medications, adverse reaction monitoring needs to be strengthened.

Special groups must strictly follow the principle of individualization when using Kaftrio.